Deutsche Bank AG Takes Position in Kenvue Inc. $KVUE

Deutsche Bank AG purchased a new position in shares of Kenvue Inc. (NYSE:KVUE) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 7,920,744 shares of the company’s stock, valued at approximately $151,365,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Kenvue by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock valued at $4,052,913,000 after acquiring an additional 1,604,040 shares during the last quarter. State Street Corp grew its holdings in Kenvue by 3.5% during the 4th quarter. State Street Corp now owns 118,865,134 shares of the company’s stock worth $2,050,424,000 after acquiring an additional 4,063,257 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Kenvue by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 49,862,574 shares of the company’s stock worth $856,778,000 after purchasing an additional 371,322 shares during the last quarter. Independent Franchise Partners LLP increased its position in shares of Kenvue by 56.3% in the 4th quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock worth $830,527,000 after purchasing an additional 17,343,785 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Kenvue in the 4th quarter valued at about $756,862,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $19.16 on Thursday. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $21.84. The firm has a market capitalization of $36.80 billion, a price-to-earnings ratio of 22.02, a price-to-earnings-growth ratio of 1.35 and a beta of 0.47. The business has a 50 day simple moving average of $19.02 and a 200 day simple moving average of $18.18. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). The business had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.29 earnings per share. On average, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Wednesday, August 12th. Kenvue’s dividend payout ratio is 96.55%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several research analyst reports. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. UBS Group lowered their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Barclays upped their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. Finally, Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.